|
DOSAGE INFORMATION
NOTE: BEFORE TAKING ANY DRUG YOU SHOULD CARFULLY CONSIDER THE DOSAGE.
THE GENERAL RULE OF THUMB IS TO TAKE 1/2 OR 1/4 OF THE DOSE FIRST TO CHECK THE STRENGTH.
ALWAYS ASK THOSE WHO YOU BUY FROM HOW STRONG THE GEAR IS.
IT'S ALWAYS BETTER TO BE SMART THAN DEAD.
Class Drug Rationale for not recommending
--------------- ---------------- ----------------------------------------
Opioids Meperidine Short (2-3 hour) duration. Repeated
administration may lead to CNS toxicity
(tremor, confusion, or seizures). High
oral doses required to relieve severe
pain, and these increase the risk of CNS
toxicity.
--------------- ---------------- ----------------------------------------
Miscellaneous Cannabinoids Side effects of dysphoria, drowsiness,
hypotension, and bradycardia preclude
its routine use as an analgesic.
---------------- ----------------------------------------
Cocaine Has demonstrated no efficacy as an
analgesic or coanalgesic in combination
with opioids.
--------------- ---------------- ----------------------------------------
Opioid agonist- Pentazocine Risk of precipitating withdrawal in
antagonists Butorphanol opioid-dependent patients. Analgesic
Nalbuphine ceiling. Possible production of
unpleasant psychotomimetic effects
(e.g., dysphoria).
--------------- ---------------- ----------------------------------------
Partial agonist Buprenorphine Analgesic ceiling. Can precipitate
withdrawal.
--------------- ---------------- ----------------------------------------
Antagonist Naloxone May precipitate withdrawal. Limit use
Naltrexone to treatment of life-threatening
respiratory depression.
--------------- ---------------- ----------------------------------------
Combination Brompton's No evidence of analgesic benefit to
preparations cocktail using Brompton's cocktail over single
opioid analgesics.
---------------- ----------------------------------------
DPT (Meperidine, Efficacy is poor compared with that of
Promethazine, other analgesics. High incidence of
and adverse effects.
Chlorpromazine)
--------------- ---------------- ----------------------------------------
Anxiolytics Benzodiazepine Analgesic properties not demonstrated
alone (e.g., except for some instances of neuropathic
alprazolam) pain. Added sedation from anxiolytics
may limit opioid dosing.
--------------- ---------------- ----------------------------------------
Sedative/ Barbiturates Analgesic properties not demonstrated.
hypnotic drugs Benzodiazepine Added sedation from sedative/hypnotic
alone drugs limits opioid dosing.
---------------------------------------------------------------------------
Routes of administration Rationale for not recommending
--------------------------------- ----------------------------------------
Intramuscular (IM) Painful. Absorption unreliable. Should
not be used for children or patients
prone to develop dependent edema or in
patients with thrombocytopenia.
--------------------------------- ----------------------------------------
Transnasal The only drug approved by the FDA for
transnasal administration at this time
is butorphanol, an agonist-antagonist
drug, which generally is not
recommended. (See opioid agonist-
antagonists above).
|
